Text Messaging Program to Prevent HIV in Cisgender Male Adolescents and Young Adults Aged 13 to 22 Across the US
Led by Center for Innovative Public Health Research · Updated on 2026-07-09
5000
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a text messaging-based HIV prevention program called Sexual Health Advocacy for Guys SHAG designed for cisgender sexual minority boys and men aged 13 to 22 across the United States. This study compares SHAG to a control group receiving messages about healthy lifestyle topics. The program aims to reduce HIV incidence and examines its impact on STI testing and use of pre-exposure prophylaxis PrEP.
Participants in the intervention group receive approximately 9 weeks of daily text messages focusing on healthy sexuality and ways to reduce HIV risk, followed by a 3-month quiet period and a week of review messages. The control group receives a similar schedule of daily text messages about healthy lifestyle topics such as self-esteem and physical exercise, with the same quiet period and review week. The messages are based on a behavioral model of preventive behavior.
During the study, participants are recruited and enrolled primarily online and digitally. Assessments include measuring HIV incidence immediately after the intervention and at 12 months post-intervention, as well as self-reported HIV incidence at several points up to 12 months. Researchers also track the proportion of participants who test for STIs and who have used PrEP or post-exposure prophylaxis PEP. Participants must have a cell phone with unlimited texting and internet access to complete surveys. The study aims to complete by December 2027.
CONDITIONS
Brief Title
Sexual Health Advocacy for Guys - a Text Messaging-based HIV Prevention Program for Guys Who Are Into Guys
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
SHAG text‑messaging HIV prevention program
Attention‑matched healthy lifestyle text‑messaging control
Typical digital PrEP support under current prevention practice
What it is
A text messaging–based HIV prevention program called SHAG, delivered over 5 months
A 5‑month text messaging program delivering general healthy lifestyle content as control
Digital reminders or texting support to promote adherence to oral PrEP under current prevention guidelines
Role in the trial
Investigational behavioral intervention aimed at HIV prevention in young cisgender males.
Attention‑matched control arm sending non‑HIV health messages.
Represents typical supportive messaging used to promote adherence to standard HIV prevention including PrEP.
Primary use
To reduce HIV risk via behavioral education and advocacy through text messages.
To serve as a neutral attention control using general health messages.
To support adherence to oral HIV prevention medication (PrEP) using digital reminders.
How it is given or performed
Delivered via routine text messages over a 5‑month period.
Delivered via text messages over 5 months covering general health topics.
Typical practice involves sending SMS reminders or digital prompts timed with PrEP dosing or refill schedules.
Evidence status
Efficacy under study; results pending publication.
Used as a comparator but no efficacy for HIV prevention intended.
No specific risks identified beyond possible message fatigue or privacy concerns.
No specific risks identified; similar minimal risk profile.
Minimal risk from text reminders; standard practice with privacy considerations.
Important limitations
Study limited to cisgender males aged 13‑22 with cell phone and internet access—results may not generalize to other groups.
Same generalizability limitations apply; non‑HIV messaging may not control for behavior attention specificity.
Evidence from adult PrEP users; may differ in youth behavioral response and context.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 13Years - 22Years
MALE
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
Assigned male sex at birth and currently identify as cisgender male
Aged between 13 and 22 years old
Had anal sex in the past 12 months
English-speaking
Own a cell phone with an unlimited text messaging plan and plan to keep the same number for 6 months
Have internet access to complete online surveys
Provide informed assent if under 18, or consent if 18 or older, including capacity to consent and positive safety assessment
Willing to take an OraQuick home HIV test or self-report negative HIV status as appropriate
Not currently enrolled in another HIV prevention program
Do not know anyone already enrolled in this trial
You will not qualify if you...
Being HIV positive
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or online)
Intervention Period
Duration - Approximately 5 months total
Participants receive daily text messages for about 9 weeks either about HIV prevention or a healthy lifestyle, followed by 3 months with no messages, then a week of review messages.
Surveys completed online at multiple timepoints
Follow-up
Duration - Up to 12 months post-intervention
Participants complete follow-up surveys and assessments up to 12 months after the intervention to measure HIV incidence and related outcomes.
Periodic online surveys
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Continued Access Study Providing Ongoing HIV Treatment for Participants from ViiV Healthcare Parent Studies
Long-Term Follow-Up Study of HIV-Infected Individuals from HIV-NAT Trials to Evaluate Clinical Outcomes and Treatment Effects
Phase 2b Study Comparing Oral VH4524184 with Standard HIV Treatment in Adults Newly Diagnosed with HIV-1
Evaluating Treatment Strategies for Managing Virologic Failure on Tenofovir, Lamivudine, and Dolutegravir TLD in People with HIV in Sub-Saharan Africa
Pilot Study of a Peer-Driven Injection Setting Intervention to Prevent HIV, Hepatitis C, and Overdose Among People Who Inject Drugs in Baltimore
Phase 1 Study of VH4011499 Safety, Tolerability, and Pharmacokinetics
with Single and Multiple Doses in Adults Without HIV
Safety and Effectiveness of JL18008 Injections Added to Standard HIV Therapy
in Adults with HIV Who Have Low Immune Response
A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Phase 12 Study to Assess Safety and Effects of Cabotegravir in Newborns Exposed to HIV-1
Phase III Study Comparing Cabotegravir and Rilpivirine Ultra Long-Acting or Long-Acting Treatments in Adolescents and Adults With Suppressed HIV
Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of Single-Dose VH4367310 in Healthy Adults Aged 18 to 55 Years
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Sexual Health Advocacy for Guys (SHAG): a randomized trial of the impact of a text-messaging program on HIV incidence and STI testing among a national sample of sexual minority cisgender adolescent and young adult men.